Data back Epigenomics' breast, prostate cancer recurrence tests
This article was originally published in Clinica
Executive Summary
Studies assessing the prognostic value of specific biomarkers incorporated into Epigenomics' two investigational tissue-based disease recurrence tests for cancers of the prostate and breast have produced positive results, the company has reported.